Robert Stott

LAS VEGAS — Effective mentorship can accelerate careers, but toxic mentoring behaviors can just as easily derail academic progress if left unchecked, Frank I. Scott, MD, MSCE, warned attendees at Crohn’s & Colitis Congress.“We know that mentorship can positively influence career trajectories,” Scott, codirector of Crohn’s & Colitis Foundation’s IBD

LAS VEGAS — Therapeutic progress for fibrostenotic Crohn’s disease has been stalled in a paradox: Antifibrotic drugs require endpoints for development, yet meaningful endpoints cannot be established without effective antifibrotic therapies.

LAS VEGAS — AGA clinical practice guidelines for inflammatory bowel disease management have undergone “major shifts” in recent years, placing diet front and center and urging patients to adhere to Mediterranean or whole-food diets. “We know that diet impacts the GI tract significantly, and it impacts the areas that we feel are the idiopathogenesis of IBD,” David Suskind, MD, professor of

Resmetirom sustained improvements in liver stiffness and several liver biomarkers among patients with metabolic dysfunction-associated steatohepatitis and compensated cirrhosis at 2 years, according to data presented at The Liver Meeting.

PHOENIX — Tulisokibart was linked to clinical, endoscopic and histologic remission in patients with ulcerative colitis following 12 weeks of induction therapy and 38 weeks of maintenance among responders, according to data presented here.The researchers also reported a strong association between clinical remission achieved with tulisokibart (MK-7240, Merck) at weeks 12 and 50 and

PHOENIX — Mycophenolate mofetil outperformed azathioprine as maintenance therapy for patients with autoimmune hepatitis, especially those with hematologic risks, according to data presented at ACG Annual Scientific Meeting.

A virtual multispecialty cancer support clinic intends to “connect the dots” to match patients with specialists within 3 days to help manage side effects of cancer treatment, including drug reactions and treatment-emergent adverse events.“About 85% of cancer patients receive their cancer treatments in community cancer centers where access to specialists like endocrinologists,

The FDA issued a complete response letter to Genentech indicating it cannot approve the company’s biologic license application seeking approval for glofitamab-gxbm as a treatment for relapsed or refractory diffuse large B-cell lymphoma.In its letter, the agency cited that data from the phase 3 STARGLO study failed to provide sufficient evidence to support glofitamab-gxbm (Columvi) as

SAN DIEGO — Inebilizumab was especially effective for patients with pancreatic and biliary immunoglobulin G4-related disease, with significantly reduced glucocorticoid use for disease control, according to analysis of the MITIGATE trial.Although data from The New England Journal of Medicine published in November 2024 confirmed that inebilizumab (Uplizna, Amgen) significantly reduced the

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous induction options for the treatment of moderately to severely active Crohn’s disease, Johnson & Johnson reported.Previously approved for ulcerative colitis in September 2024, Tremfya (guselkumab) is now the third IL-23p19 specific inhibitor approved for

The AGA reported that it could not issue a recommendation for or against the use of computer-aided detection in colonoscopy due to “very low certainty of evidence” and “the close tradeoff between the desirable and undesirable effects.”The association cautioned that, although AI is credited with increased detection of low-risk colorectal polyps during colonoscopy, there

The ACG has released its first guidance for gastric premalignant conditions, such as atrophic gastritis, gastric intestinal metaplasia and dysplasia, in sync with surveillance recommendations established for the colon and esophagus.Although the United States is considered to have low rates of gastric cancer incidence, “specific U.S. populations, such as immigrants from high-gastric cancer

The U.S. Multi-Society Task Force on Colorectal Cancer has released updated guidance establishing a “reasonable benchmark” for the quality of bowel preparation prior to a colonoscopy exam.The task force — comprised of ACG, AGA and ASGE — last updated its recommendations on the level of adequacy for bowel cleansing in 2014. The new guidance was simultaneously published in

In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses the looming threat of gastroenterology workforce shortage, alongside insights from a roundtable of ACG presidents on how we might still avoid it. “I think we all feel it on some level,” Loftus said. “By some estimates, there is projected to be a shortage of over 1,000 gastroenterologists over the next few years. I

In a new clinical practice guideline, the AGA provided evidence-based recommendations for either antiviral prophylaxis or continued surveillance to manage hepatitis B virus reactivation in patients receiving immunosuppressive therapy. “HBV reactivation is generally a consequence of chronic immunosuppression, induced either by drug therapy or by pathologic immunosuppression,” Faisal S.

Eight years ago, Ocaliva was a prospective lifesaver for patients with primary biliary cholangitis who failed to adequately respond to first-line ursodeoxycholic acid. However, the once-promising drug now finds itself struggling to deliver.

PHILADELPHIA — On-demand vonoprazan effectively reduced heartburn symptom severity in patients with nonerosive reflux disease within 1 hour of treatment, according to data presented at the ACG Annual Scientific Meeting. “On-demand treatment for nonerosive reflux disease is suitable primarily for patients who do not have a high frequency of heartburn,” Ronnie Fass, MD, MACG,

PHILADELPHIA — A “high prevalence” of extremity repetitive use injury symptoms were reported among endoscopists, which negatively affected performance, according to a presenter at the ACG Annual Scientific Meeting. “A [2015] ASGE survey reported that 78% of endoscopists had an extremity repetitive use injury, or ERI,” Daryl Ramai, MD, MPH, MSc, an advanced endoscopy

PHILADELPHIA — Iqirvo demonstrated significant biochemical response and alkaline phosphatase normalization in patients with both early- and advanced-stage primary biliary cholangitis, according to late-breaking data presented here. “Elafibranor — a peroxisome proliferator-activated receptor agonist — has demonstrated significant biochemical response in 51% vs. 4% of

PHILADELPHIA — Zymfentra as monotherapy was no more effective when combined with immunosuppressants for maintenance therapy in patients with Crohn’s disease or ulcerative colitis, according to post-hoc analysis presented here. “[Zymfentra] is a subcutaneous form of infliximab, which has shown superior efficacy over placebo for maintenance therapy up to 1 year in patients